Qianqian Wang

Qianqian Wang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
JHJing He
Jing He
GDGouping Ding
Gouping Ding
YTYixuan Tang
Yixuan Tang
QWQianqian Wang
Qianqian Wang
Immune checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 have achieved groundbreaking clinical success in multiple cancers; however, a large proportion of patients experience primary or acquired resistance. This review synthesizes the complex mechanisms underlying resistance to PD-1/CTLA-4 blockade and surveys emerging strategies to overcome them. Resistance arises from multifaceted interactions among tumor-intrinsic alterations (e.g., epigenetic silencing of antigen presentation machinery via EZH2/PRC2, oncogenic pathway–driven upregulation of PD-L1, genetic loss of IFNγ pathway components such as JAK1/2 or B2M), immune cell dysfunction (e.g., T cell exhaustion with co-expression of inhibitory receptors including PD-1, TIM-3, and LAG-3, metabolic and epigenetic T cell reprogramming, suppressive regulatory T cells), and stromal microenvironmental factors (e.g., hypoxia-inducible factors, immunosuppressive metabolites like IDO-mediated kynurenine, tumor-associated macrophages and MDSCs, aberrant angiogenesis). To counteract these diverse resistance mechanisms, a spectrum of novel therapeutic approaches is under development. Mechanism-targeted monotherapies include agents that restore tumor immunogenicity (e.g., epigenetic modulators to upregulate MHC expression), reinvigorate exhausted T cells (e.g., blockade of alternative checkpoints such as LAG-3), and reprogram the suppressive tumor microenvironment (e.g., inhibitors of immunosuppressive myeloid pathways). In parallel, rational combination therapies are being explored, pairing ICIs with chemotherapy (to induce immunogenic cell death and enhance T cell infiltration), molecularly targeted drugs (to disrupt oncogenic immune-evasion signals), or immune modulators (e.g., IL-2 or IL-18 variants to boost effector T cell function). Furthermore, emerging predictive biomarkers and machine learning-based signatures (e.g., soluble checkpoint levels, inflammatory indices, tumor transcriptomic scores) are improving the ability to anticipate ICI resistance and guide personalized escalation of therapy. Overall, this synthesis highlights the recent insights into resistance biology and promising avenues to extend the durable benefits of PD-1/CTLA-4 blockade to a larger proportion of patients.

1 February 2026 in Journal of Multidisciplinary Healthcare
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
JHJing He
Jing He
GDGouping Ding
Gouping Ding
YTYixuan Tang
Yixuan Tang
QWQianqian Wang
Qianqian Wang
Immune checkpoint inhibitors (ICIs) have reshaped oncology, yet overall response rates remain modest and resistance is common, driven by tumor heterogeneity and evolving tumor–immune crosstalk. Established biomarkers (PD-L1, tumor mutational burden, microsatellite instability) provide incomplete prediction. Multi-omics profiling across genomic, transcriptomic, proteomic, epigenomic, metabolomic and microbiomic layers offers a systems-level view of malignant and immune states, uncovering determinants of ICI efficacy such as lineage plasticity, stromal remodeling, immunometabolic reprogramming and microbiome-associated immune modulation. Artificial intelligence (AI) is uniquely positioned to fuse these heterogeneous data, learn non-linear cross-layer signatures, and enable interpretable predictions using approaches such as SHAP and Grad-CAM. Representative models link routine histology or imaging to molecular phenotypes, stratify patients beyond single biomarkers, and may nominate rational combinations that target oncogenic pathways, lactate-driven immune suppression, or the gut microbiome. In this narrative review, we synthesize recent AI–multi-omics advances for response modeling, immune-relevant tumor subtyping, and clinical translation, including radiomics/pathomics integration and liquid-biopsy–based monitoring, as well as emerging applications in toxicity risk prediction. We also discuss barriers to implementation—platform heterogeneity, limited prospective validation, bias, interpretability and cost—and outline future directions, including single-cell and spatial multi-omics integration, federated learning and generative modeling to improve robustness and equity of precision immunotherapy.

7 February 2026 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
JWJunjie Wang
Junjie Wang
QWQianqian Wang
Qianqian Wang
GDGouping Ding
Gouping Ding
YHYiping Huang
Yiping Huang
YFYeqian Feng
Yeqian Feng
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 can produce durable remissions in multiple solid tumors, yet primary and acquired resis

19 March 2026 in Discover Oncology
Verified
Journal Article
Open access
XWXiaodong Wang
Xiaodong Wang
DXDi Xiong
Di Xiong
SCSongli Cui
Songli Cui
BDBincheng Duan
Bincheng Duan
YHYiping Hung
Yiping Hung
QWQianqian Wang
Qianqian Wang
Artificial intelligence (AI) is reshaping oncology by extracting clinically actionable signals from complex cancer data and accelerating drug development. In this narrative review, we summarize how machine learning and deep learning models support cancer phenotyping, including tumor detection, molecular subtyping, prognosis, and treatment response prediction across histopathology, radiology, and multi-omics data. We then discuss AI-enabled virtual screening, drug repurposing, generative molecular design, and hybrid computational–experimental pipelines that streamline oncology drug discovery and optimization. Cross-cutting limitations are examined, including data quality and representativeness, class imbalance, bias and fairness, model interpretability, and ethical, privacy, and regulatory challenges in clinical deployment. Finally, we highlight emerging directions such as multimodal foundation models, federated learning, AI stewardship, and patient-specific digital twins, and outline a roadmap for integrating trustworthy AI into precision oncology. Realizing the full potential of AI will require rigorous validation, transparent reporting, and close collaboration between clinicians, data scientists, regulators, and patients to ensure equitable, patient-centred benefit.

25 August 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
GDGouping Ding
Gouping Ding
JHJing He
Jing He
YHYiping Huang
Yiping Huang
QWQianqian Wang
Qianqian Wang
This bibliometric analysis maps global research trends on PARP inhibitors (PARPis) in ovarian cancer from January 2021 to May 2025, utilizing 1,434 publications retrieved from the Web of Science Core Collection. Employing Bibliometrix, VOSviewer, and CiteSpace, the study quantifies contributions across countries, institutions, authors, and research foci. Key findings reveal the United States (440 publications) and China (352) as leading producers, with UNICANCER (287 publications) and Memorial Sloan Kettering Cancer Center (61) as top institutions. Keyword clustering identified six research themes: PARPi resistance mechanisms (Cluster 1, red) emerged as the dominant focus, followed by immunotherapy combinations for platinum-resistant disease (Cluster 2, green), maintenance therapy (Cluster 3, blue), BRCA mutations (Cluster 4, yellow), applications beyond ovarian cancer (Cluster 5, purple), and anti-angiogenic mechanisms (Cluster 6, light blue). Temporal analysis highlighted an evolution from foundational research (e.g., DNA repair pathways) toward clinical translation (e.g., maintenance therapy optimization). Notable citation bursts surrounded clinical milestones, including the SOLO1 trial’s 7-year overall survival data (burst strength: 23.99), underscoring the field’s emphasis on survival outcomes. Critical gaps persist in understanding resistance mechanisms and developing immuno-combination strategies, which constituted only 4.8% of keyword frequency. The study underscores the need for intensified research into resistance mitigation and transnational collaboration, particularly between established Euro-American networks and emerging East Asian hubs, to address therapeutic challenges and optimize clinical impact.

21 January 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
DXDi Xiong
Di Xiong
SCSongli Cui
Songli Cui
BDBingchen Duan
Bingchen Duan
YHYiping Huang
Yiping Huang
QWQianqian Wang
Qianqian Wang
Background: Ovarian cancer remains lethal and shows limited response to immunotherapy partly due to immune evasion. We mapped global research trends on ovarian cancer immune evasion during 2015–2024. Methods: Web of Science Core Collection and Scopus were searched on 6 Oct 2025 for English articles and reviews published 1 Jan 2015–31 Dec 2024. Records were merged and deduplicated in R (bibliometrix). Productivity, collaboration, keywords, thematic clusters, and burst terms and citations were analyzed using bibliometrix, VOSviewer, and CiteSpace. Results: A total of 496 publications from 202 sources were included, showing rapid growth (annual growth rate ~24.6%) with a marked rise after 2020. The United States and China contributed the most output, whereas international collaboration was limited (~9.7% of authors with multiple-country affiliations). Keyword co-occurrence revealed major themes in immunotherapy, tumor microenvironment remodeling, immune checkpoint regulation, resistance mechanisms, and genetic/epigenetic modulation. Emerging hotspots highlighted tumor-associated macrophages and STAT3-centered signaling as key drivers of immune suppression and therapeutic resistance. Conclusion: Research on ovarian cancer immune evasion is expanding quickly and is shifting toward actionable targets and combination strategies. Strengthening cross-country collaboration and focusing on TME- and STAT3/TAM-directed interventions may accelerate translation and improve immunotherapy outcomes.